Nifty outlook & stock calls by Anand Rathi: Buy TCS, Torrent Pharma

TCS' stock has provided a breakout from a descending triangle pattern on the daily chart

buy, sell, stocks, share
TCS has surpassed its 21-DMA placed at 2,260
Nilesh Jain Mumbai
2 min read Last Updated : Sep 04 2020 | 8:21 AM IST
BUY NIFTY | TARGET: 11,650 | STOP LOSS: 11,450

The Nifty index found the support of a rising trend line and rebounded from the same. The momentum indicators and oscillators on the weekly scale are very well in 'buy' mode. Hence, one should remain on the long side of the Nifty index and utilise every dip as a buying opportunity till the time it doesn’t break its major trend line which is placed at 11,450 levels. 

BUY TCS | TARGET: Rs 2,360 | STOP LOSS: Rs 2,260

The stock has provided a breakout from a descending triangle pattern on the daily chart. It is trading well above its short-term and long-term moving averages. The momentum indicators and oscillators are very well in the 'buy' mode on daily as well as weekly scales which hints of a further positive momentum in the counter. It has also surpassed its 21-DMA which is placed at 2,260 which will now act as immediate support.

BUY TORNTPHARMA | TARGET: Rs 2,900 | STOP LOSS: Rs 2,740

The counter has provided a breakout from a falling channel and the momentum indicator RSI has also reversed from the oversold territory. It also trading well above its long term 200-day simple moving average. The overall pharma sector is poised for a breakout on the charts.

BUY KEC | TARGET: Rs 350 | STOP LOSS: Rs 310

The stock is in a secular uptrend and also making a higher top and higher bottom formation on the daily chart. The counter has reversed after witnessing some profit booking from higher levels. The momentum indicator and oscillator are in 'buy' mode on the weekly scale which hints of further positive momentum in the counter.
Disclaimer: Nilesh Jain is Technical and Derivatives Research analyst at Anand Rathi Shares and Stock Brokers. He may have positions in one or all of the above mentioned stocks. Views are personal.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :MarketsMarket technicalsTCSNifty OutlookTorrent PharmaKEC International

Next Story